Skip to main content
padlock icon - secure page this page is secure

Antibody-Drug Conjugates in Targeted Therapy for Cancer

Buy Chapter:

$68.00 + tax (Refund Policy)

An antibody-drug conjugate consists of a potent cytotoxic drug attached to a monoclonal antibody specially targeted on cancer associated antigen. The antigen targeted chemotherapy can improve therapeutic index by increasing potential efficacy and decreasing systemic toxicity. In this review, we described the study and the progress in antibody engineering, the process of drug selection, and the development of linker to optimize the clinical trials. We also discussed about the possible mechanism of cell death induced by an antibody- drug conjugate and the potential resistance to an antibody-drug conjugate. Nonetheless, the successful results from Gentuzumab ozogamicin and other encouraging clinical trials will continue to drive the preclinical development of antibody-drug conjugates.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: auristatin; calicheamicin derivative; cancer immunotherapy; chimeric antibodies; complement dependent cytotoxicity; full human antibodies; rituximab

Document Type: Research Article

Publication date: March 1, 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more